Cette méta-analyse, menée à la Stanford University, renforce le sentiment d’absence de changements de fond, favorables à l’amélioration des conditions de travail, des médecins et professionnels de ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while ...

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its ...

The Company is guiding to Q4 2024 revenues of $36 to $38 million. The Company anticipates Core revenues in Q4 2024 of $35 to $37 million, which includes $1 to $2 million of Risk Assessment testing ...

Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in December 2024 ...

Seer will host a conference call to discuss the third quarter 2024 financial results on Wednesday, November 6, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can ...

Total operating expenses for the third quarter of 2024 were $45.6 million, a 29% increase compared to $35.5 million for the same period last year. The increase was mainly driven by the addition of ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

Financial Condition As of September 30, 2024, the Company had $3.7 million in cash, short-term notes payable of $5.0 million, and $1.0 million of long-term debt relating to Spectral IP. Cash at ...

Interim phase 1 clinical data with potentially best-in-class CDK9 inhibitor, PRT2527, in hematological malignancies to be presented at the American Society of Hematology Annual Meeting in December ...

Strengthens board with appointments of Dr. Karen Smith and Dr. Luke Walker Cash and cash equivalents of $84.8 million as of September 30, 2024 PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Context ...

CHARLESTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...